Browse Studies — Arctuva

Phase 3

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with…

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Chronic LymphocyticSmall-Cell Lymphoma+3 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT05947851

Phase 1

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for B-cell Leukemias

Background: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers th…

Leukemia, Lymphocytic, Chronic, B-CellB-Lymphocytic Leukemia, ChronicB-Cell Chronic Lymphocytic Leukemia+4 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06364423

Genetic Epidemiology of Lymphoproliferative Disorders

Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and t…

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell+2 more

Estimated

~$10 – $750

Mayo ClinicNCT00626496